Rajan Sharma is ranked #1065 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Rajan Sharma

Q: How accurate are Rajan Sharma's stock ratings?

About 59% of Rajan's ratings were profitable over a one-year hold, with an average return of +10.1% per rating, measured by 13Foresight from historical prices.

Goldman Sachs

Wall Street Analyst

★★★☆☆

#1065

on 13Foresight · ranked by our own returns

59%

Success Rate

+9.2%

Average Return

22 of 37 calls profitable · +0.6% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

🔒 3-year track record is Pro. Showing 1-year — upgrade.

📈 Across the calls we could measure, roughly 59% of Rajan Sharma's ratings turned a profit when each position was held for 1 year — averaging +9.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

48 Buy 17 Hold 3 Sell

Rajan's Stock Coverage 28 ratings · 2026-08-14

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
AUTL Autolus Therapeutics	Aug 11, 2026	BUY	Strong Buy +385.0% avg upside 16 analysts	$5.80 173.52% Upside	-7.7%	·
BCAX Bicara Therapeutics Inc.	Aug 11, 2026	HOLD	Strong Buy +34.5% avg upside 15 analysts	$20.00 18.89% Downside	-1.4%	·
GB:0MGB Genmab A/S	Aug 07, 2026	BUY	Buy -2.0% avg upside 23 analysts	$216.74 89.28% Downside	·	·
IMCR Immunocore Holdings	Aug 06, 2026	BUY	Strong Buy +88.0% avg upside 22 analysts	$74.00 112.97% Upside	-0.8%	·
GB:0NZT UCB SA	Aug 03, 2026	BUY	Buy +0.5% avg upside 19 analysts	$295.00 32.57% Upside	·	·
GB:AZN AstraZeneca	Jul 28, 2026	BUY	Strong Buy +25.3% avg upside 26 analysts	$16070.00 37.71% Upside	-9.8%	·
GB:GSK GlaxoSmithKline	Jul 28, 2026	HOLD	Hold +4.8% avg upside 25 analysts	$1890.00 1.52% Upside	-3.5%	·
GB:0QW0 arGEN X	Jul 24, 2026	BUY	Strong Buy -18.6% avg upside 24 analysts	$907.00 21.27% Upside	·	·
IMTX Immatics	May 12, 2026	BUY	Strong Buy +90.1% avg upside 15 analysts	$12.20 25.57% Upside	-17.1%	·
VALN Valneva	Apr 22, 2026	SELL	Strong Buy +101.4% avg upside 6 analysts	$4.90 11.73% Downside	-35.8%	·
GMAB Genmab	Apr 22, 2026	BUY	Buy +13.4% avg upside 27 analysts	$30.50 2.87% Downside	+15.3%	·
DBVT DBV Technologies SA - American	Apr 09, 2026	SELL	Strong Buy +71.5% avg upside 15 analysts	$5.81 58.94% Downside	+34.5%	·
FR:DBV DBV Technologies	Apr 09, 2026	SELL	Hold +119.6% avg upside 3 analysts	$1.01 59.03% Downside	+30.5%	·
IT:PHIL Philogen SpA	Apr 09, 2026	HOLD	Hold -28.3% avg upside 2 analysts	$18.00 25.52% Downside	+20.6%	·
ARGX Argenx Se	Feb 26, 2026	BUY	Strong Buy -8.7% avg upside 47 analysts	$910.00 3.90% Upside	+10.3%	·
CATX Perspective Therapeutics	Feb 17, 2026	BUY	Strong Buy +257.2% avg upside 22 analysts	—	-34.0%	·
FR:IPH Innate Pharma SA	Jan 09, 2026	HOLD	Buy +333.5% avg upside 5 analysts	—	-1.9%	·
KNSA Kiniksa Pharmaceuticals	Jul 30, 2025	BUY	Strong Buy -0.9% avg upside 11 analysts	$45.00 42.52% Downside	+160.2%	·
FR:VLA Valneva	Mar 21, 2025	HOLD	Strong Buy +264.4% avg upside 3 analysts	$3.30 35.73% Upside	+28.2%	·
HALO Halozyme	Oct 03, 2024	HOLD	Strong Buy -35.2% avg upside 20 analysts	—	+14.1%	·
ZLDPF Zealand Pharma	Aug 16, 2024	BUY	Buy +57.2% avg upside 11 analysts	$170.94 229.97% Upside	-59.4%	·
CH:IDIA Idorsia Ltd	Jul 30, 2024	HOLD	Hold -27.1% avg upside 8 analysts	$2.00 70.08% Downside	+36.6%	·
CH:NOVN Novartis AG	May 30, 2024	BUY	Buy -9.8% avg upside 32 analysts	—	+4.5%	·
GSK GlaxoSmithKline	May 30, 2024	HOLD	Hold -13.4% avg upside 19 analysts	$47.00 6.57% Downside	-2.7%	·
ROIV Roivant Sciences	Dec 20, 2023	BUY	Strong Buy -2.0% avg upside 17 analysts	—	+16.2%	·
FR:IPN Ipsen	Feb 13, 2023	HOLD	Hold -20.3% avg upside 17 analysts	$100.00 35.38% Downside	-0.9%	·
IT:REC Recordati Industria Chimica e Farmaceutica SPA	May 16, 2022	HOLD	Hold -8.5% avg upside 7 analysts	$44.00 16.51% Downside	+10.5%	·
HCM HUTCHMED	May 04, 2022	HOLD	Strong Buy +152.8% avg upside 9 analysts	$20.00 63.20% Upside	+23.6%	·

🔒 23 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Rajan Sharma — Frequently Asked Questions

How accurate are Rajan Sharma's stock ratings?

Based on the calls 13Foresight could measure, about 59% of Rajan's ratings were profitable over a one-year hold, with an average return of +10.1% per rating, or +1.6% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Rajan ranked on 13Foresight?

Rajan Sharma is currently ranked #1065 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Rajan cover?

Rajan most recently has ratings on AUTL, BCAX, GB:0MGB, IMCR, GB:0NZT, GB:AZN, GB:GSK, GB:0QW0, IMTX, VALN, GMAB, DBVT and 16 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rajan Sharma

Rating Distribution

Welcome to 13Foresight!